The efficacy of intralesional metronidazole compared to intralesional glucantime in the therapeutic therapy of cutaneous leishmaniasis
DOI:
https://doi.org/10.66344/jpad.v32i2.1919Abstract
Objective To assess the effectiveness of intralesional metronidazole vs. intralesional glucantime in the therapy of cutaneous leishmaniasis.
Methods A randomized controlled trial, conducted in the Department of Dermatology, Lady Reading Hospital, Peshawar from the 1st of February to the 10th of June 2020. A total of 60 patients of both gender with cutaneous leishmaniasis <3 months duration were included. 30 patients were in the intralesional metronidazole group (Group A) while 30 patients were in the intralesional glucantime group (Group B). Efficacy from both groups was noted.
Results The participants age ranged in this study from 15 to 50 years, with Group A having a mean age of 30.700± 6.13 years and Group B with a mean age of 30.500 ±5.72 years. In this study Group A having mean disease period of 1.4000±0.49 months, while Group B had a mean disease period of 1.6000±0.46 months. In Group A, the mean weight was 66.63±8.21 kg, whereas in Group B, it was 69.066±9.59 kg. Efficacy was demonstrated in 26.7 percent of Group A patients against 73.3 percent of Group B patients (p=0.000).
Conclusion In our study intralesional glucantime is more effective and safe in the treatment of cutaneous leishmaniasis. Despite the fact that metronidazole was found to be unsuccessful in this trial, we feel that the quest for a pain free, readily applied, and effective treatment modality with minimum adverse effects for the therapy of cutaneous leishmaniasis is essential.
References
1. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671
2. Du R, Hotez PJ, Al-Salem WS, Acosta-Serrano A, Old world cutaneous leishmaniasis and refugee crises in the Middle East and North Africa. PLoS Negl Trop Dis. 2016;10(5):e0004545.
3. Prieto-Barja P, Pescher P, Bussotti G, Dumetz F, Imamura H, Kedra D, et al. Haplotype selection as an adaptive mechanism in the protozoan pathogen Leishmania donovani. Nat Ecol Evol. 2017;1(12):1961-9.
4. Hotez PJ, Woc-Colburn L, Bottazzi ME. Neglected tropical diseases in Central America and Panama: review of their prevalence, populations at risk and impact on regional development. Int J Parasitol. 2014;44(9):597-603.
5. Karimkhani C, Wanga V, Coffeng LE, Naghavi P, Dellavalle RP, Naghavi M. Global burden of cutaneous leishmaniasis: a cross-sectional analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016;16(5):584-91.
6. Hurrell BP, Regli IB, Tacchini-Cottier F. Different leishmania species drive distinct neutrophil functions. Trends Parasitol. 2016;32(5):392-401.
7. Chahed MK, Bellali H, Ben Jemaa S, Bellaj T. Psychological and psychosocial consequences of zoonotic cutaneous leishmaniasis among women in Tunisia: preliminary findings from an exploratory study. PLoS Negl Trop Dis. 2016;10(10):e0005090.
8. Mapar MA, Omidian M. Intralesional injections of metronidazole versus meglumine antimoniate for the treatment of cutaneous leishmaniasis. Jundishapur J Microbiol. 2010;3(2):79-83.
9. Somaratne VN, Ranawaka RR, Jayaruwan HM, Wipuladasa DM, de Silva SHP. Randomized, double-blind study on intralesional metronidazole versus intralesional sodium stibogluconate in Leishmania donovani cutaneous leishmaniasis. J Dermatolog Treat. 2018:1-5.
10. Jaffary F, Nilforoushzadeh MA, Siadat A, Haftbaradaran E, Ansari N, Ahmadi E. A comparison between the effects of glucantime, topical trichloroacetic acid 50% plus glucantime, and fractional carbon dioxide laser plus glucantime on cutaneous leishmaniasis lesions. Dermatol Res Pract. 2016;2016:6462804.
11. Kashani MN, Firooz A, Eskandari SE, et al. Evaluation of meglumine antimoniate effects on liver, kidney and pancreas function tests in patients with cutaneous leishmaniasis. Eur J Dermatol. 2007;17:513-5.
12. Radmanesh M, Falahzadeh A, Dowraghi HF. Weekly versus every 3 days intralesional meglumine antimoniate therapy for cutaneous leishmaniasis. J Dermatol Treat. 1998;9:231-3.
13. Bogenrieder T, Lehn N, Landthaler M, Stolz W. Treatment of old world cutaneous leishmaniasis with intralesionally injected meglumine antimoniate using a Dermojet device. Dermatology. 2003;206:269-72.
14. Asilian A, Sadeghinia A, Faghihi G, Momeni A, Amini Harandi A. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis. Ann Trop Med Parasitol. 2003;97:493-8.
15. Aronson NE, Wortmann GW, Johnson SC. et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent US military experience. Clin Infect Dis. 1998;27:1457- 64.
16. Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A. Unresponsiveness to glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med. 2006;3(5):e162.
17. Molavi A, LeFrock JL, Prince RA. Metronidazole. Med Clin North Am. 1982; 66: 121-33. 85. Long PI. Cutaneous leishmaniasis treated with metronidazole. JAMA. 1973;223:1378-9.
18. Pedersen JK, Sawicki S. Metronidazole therapy for cutaneous leishmaniasis. Arch Dermatol. 1975;111:1343-4.
19. Beltran F, Gutierrrez M, Biagi F: Utilite du metronidazole dans le traitement de la leishmaniose cutanee Mexicaine. Bull Soc Pathol Exot.1967;50:61- 4.
20. Griffiths WAD, Sodeify M. Use of metronidazole in cutaneous leishmaniasis. Arch Dermatol. 1976;112:1791.
21. Asher W, Chaim C. Cutaneous leishmaniasis: In efficacity of treatment with metronidazole. Arch Dermatol. 1977;113:1299.
22. Walton BC, Paulson JB, Aryona MA, Peterson CA. American cutaneous leishmaniasis, inefficacy of metronidazole in treatment. JAMA. 1974;228:1256-8.
23. Al-Waiz M, Sharquie KE, Al-Assir M. Treatment of cutaneous leishmaniasis by intralesional metronidazole. Saudi Med J. 2004;25(10):1512-3.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Ghafoor Ullah, Tariq saleem, Farhad Ali
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
